1. Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-naïve and treatment-experienced individuals in Botswana.
- Author
-
Zuze BJL, Radibe BT, Choga WT, Bareng OT, Moraka NO, Maruapula D, Seru K, Mokgethi P, Mokaleng B, Ndlovu N, Kelentse N, Pretorius-Holme M, Shapiro R, Lockman S, Makhema J, Novitsky V, Seatla KK, Moyo S, and Gaseitsiwe S
- Subjects
- Humans, Botswana, Drug Resistance, Viral genetics, Anti-Retroviral Agents therapeutic use, Mutation, Genotype, HIV-1 genetics, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, HIV Infections drug therapy
- Abstract
Importance: Fostemsavir (FTR) is a newly licensed antiretroviral drug that has been shown to have activity against HIV-1. The mechanism of action of FTR is different from all currently available antiretrovirals (ARVs), and as such, it offers hope for HIV-1 suppression in those people with HIV (PWH) who harbor HIV-1 variants with drug resistance mutations to currently used ARVs. Using 6,030 HIV-1 sequences covering the HIV-1 envelope from PWH in Botswana who are antiretroviral therapy (ART) naïve as well as those who are failing ART, we explored the sequences for FTR resistance-associated polymorphisms. We found the prevalence of FTR polymorphisms to be similar in both ART-naïve and ART-experienced individuals with VF in this setting, with no prior FTR exposure. Further studies on the phenotypic impact of these polymorphisms are warranted to guide how to monitor for FTR resistance., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF